<DOC>
	<DOC>NCT01486251</DOC>
	<brief_summary>The purpose of this study is to evaluate and quantify the dynamic modifications of tumor blood perfusion on axitinib therapy in patients with refractory mCRC for each dose of Axitinib.</brief_summary>
	<brief_title>Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Patients with histologically confirmed diagnosis of CRC Measurable metastatic disease to the liver in proven disease progression (according to RECIST criteria) at baseline (within 4 weeks prior to study entry), with at least one lesion &gt; 2cm considered appropriate for DCEUS examination Previously exposed to at least, irinotecan, oxaliplatin and a fluoropyrimidine, all 3 administered at optimal doses, over one or two chemotherapy (CT) lines for metastatic disease with a clear resistance to these drugs. Previous exposure to bevacizumab and/or antiEGFR monoclonal antibody is allowed. Age ≥18 years; Performance Status (PS) 02 and life expectancy &gt; 3 months. Adequate biological functions: Neutrophils ≥ 1.5 x 109/L; Platelets ≥ 100 x 109/L; Hemoglobin &gt; 9 g/dl; Creatinine clearance &gt; 30 ml/min (cockcroft &amp; Gault formula). Serum bilirubin &lt; 1,5 x the upper normal limit (UNL) and AST/ALT &lt; 5 x UNL. Signed written informed consent Female patients with childbearing potential (&lt;2 years after last menstruation) and male must use effective means of contraception during the study treatment and at least 6 months after the last study drug administration.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>